- cafead   Dec 08, 2022 at 10:42: AM
via Novartis declared a Phase III success for its drug iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria, a rare disorder in which flawed red blood cells are attacked by the immune system, forcing patients to get blood transfusions.
article source
article source